CD19 and diffuse large B-cell lymphoma: Despite the superiority of second-line CAR-T cell therapy over standard immunochemotherapy with or without ASCT11,12, less favorable survival following CD19 CAR-T cell therapy in patients with primary refractory DLBCL compared with that in patients with relapsed DLBCL was reported in both TRANSFORM and ZUMA-7 trials.